AI-Driven Multimodal Chromatography for Next-Generation HIV-1 Envelope Glycoprotein Purification

A novel, machine learning-based multimodal chromatography system for purifying HIV-1 envelope glycoprotein, enabling real-time optimization of purification conditions and formulation for improved yield, purity, and efficacy.

The original patent described a multimodal chromatography method for HIV-1 envelope glycoprotein purification, but it relied on empirical optimization and lacked real-time process control. This new inventive concept addresses the limitations of the original patent by integrating machine learning-based predictive analytics, real-time process control, and advanced multimodal chromatography resins to achieve unprecedented purification efficiency and flexibility.

The AI-driven multimodal chromatography system comprises a multimodal chromatography module, a machine learning-based predictive analytics module, and a real-time process control module. The predictive analytics module utilizes protein structure and function data to optimize purification conditions, predict optimal binding conditions for HIV-1 envelope glycoprotein, and enable real-time process control. The multimodal chromatography module employs advanced resins with diverse binding properties, selected based on machine learning-based predictions. The system enables integrated purification and formulation, allowing for real-time optimization of formulation conditions based on protein structure and function data.

The new claims introduce a paradigm shift by integrating machine learning-based predictive analytics and real-time process control into multimodal chromatography, enabling unprecedented purification efficiency, flexibility, and adaptability. The inventive concept's novelty lies in the synergistic combination of advanced multimodal chromatography resins, machine learning-based predictive analytics, and real-time process control, which overcomes the limitations of the original patent and enables next-generation HIV-1 envelope glycoprotein purification.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, incorporation of additional analytical techniques, or integration with other purification methods. Variations of the system could be designed for specific HIV-1 envelope glycoprotein variants or for purification of other biomolecules.

The AI-driven multimodal chromatography system has significant commercial potential in the biotechnology and pharmaceutical industries, particularly for the development of HIV vaccines and therapies. The system's ability to optimize purification conditions and formulation in real-time could lead to improved yield, purity, and efficacy, reducing production costs and increasing product quality.